Innoviva is a Burlingame, California biopharmaceutical company that earns royalties on lung medicines and sells hospital critical care and antibiotic drugs. It last closed at $18.30 on Nov 17, down 1.03% on the day.
Only 1 firm rated INVA in the past 90 days, not enough for a consensus
Average 12-month target
$34.00
▲ 85.8% upside
Based on 1 analyst who set a price target on INVA in the past 90 days. The average target is $34.00, with a high of $34.00 and a low of $34.00, compared with the last close of $18.30.
Low $34.00Avg $34.00High $34.00
Blue marker: last close $18.30
Highest target$34.00
Average target$34.00
Lowest target$34.00
Latest rating changes
OppenheimerTarget lowered
Nov 5Buy$35 → $34
OppenheimerAssumed coverage
Sep 23Buy$35
Cantor FitzgeraldMaintained
Aug 7Buy$34
BTIGMaintained
Jun 22Buy$42
HC Wainwright & Co.Reiterated
Jun 1Buy$46
Date
Firm
Action
Rating
Price target
Nov 5
Oppenheimer
Target lowered
Buy
$35 → $34
Sep 23
Oppenheimer
Assumed coverage
Buy
$35
Aug 7
Cantor Fitzgerald
Maintained
Buy
$34
Jun 22
BTIG
Maintained
Buy
$42
Jun 1
HC Wainwright & Co.
Reiterated
Buy
$46
Loading…
Technical Analysis
INVA · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 10% below its 20 day and 12% below its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the 52 week low at $18.28, and the nearest resistance the Pivot at $18.39.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 3.4%/day
Key levels
$25.1552 week high+37.4%
$21.87200 day average+19.5%
$21.33Swing high (Aug 26)+16.6%
$21.00100 day average+14.8%
$20.5850 day average+12.5%
$20.0820 day average+9.7%
$18.49Pivot R1+1.0%
$18.39Pivot+0.5%
$18.30Last close
$18.2852 week low−0.1%
$18.19Pivot S1−0.6%
Indicators
RSI (14)
27.34
Oversold below 30
Oversold
MACD
-0.64
Below its signal line
Bearish
Stochastic
5.2
Near the bottom of its range
Oversold
ADX (14)
23.4
Weak trend
Williams %R
-99.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-120.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−12.6%
Change over 10 sessions
Bearish
ATR (14)
$0.62
Typical daily range, 3.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.6%/day
Key levels
$25.1552 week high+37.4%
$21.87200 day average+19.5%
$21.33Swing high (Aug 26)+16.6%
$21.00100 day average+14.8%
$20.5850 day average+12.5%
$20.0820 day average+9.7%
$18.49Pivot R1+1.0%
$18.39Pivot+0.5%
$18.30Last close
$18.2852 week low−0.1%
$18.19Pivot S1−0.6%
Indicators
RSI (14)
33.10
Weak, oversold below 30
Neutral
MACD
-0.64
Below its signal line
Bearish
Stochastic
5.0
Near the bottom of its range
Oversold
ADX (14)
16.4
No clear trend
Williams %R
-99.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-300.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−11.4%
Change over 10 sessions
Bearish
ATR (14)
$1.21
Typical daily range, 6.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for INVA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how INVA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow INVA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How INVA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INVA is in one of them and how their past INVA trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Innoviva
Innoviva is a biopharmaceutical company based in Burlingame, California. It earns royalties on inhaled medicines for asthma and chronic lung disease that GSK develops and sells. It also markets hospital medicines for critical care and serious bacterial infections, such as treatments for septic shock and pneumonia, which are used by hospitals and their patients. The company also holds stakes in other healthcare companies.